In this episode, John M. Burke, MD, a leading expert, and Amy Esposito, FNP-C provide expert insights on key data presented at the 2022 ASCO annual conference for CLL/SLL regarding:

• Updated response and safety results after 3 years of follow-up from the phase II CAPTIVATE study of ibrutinib and venetoclax in patients with previously untreated CLL
• Updated response and remission rates after 4 years of follow-up from a phase II trial of obinutuzumab, ibrutinib, and venetoclax in patients with either treatment-naïve or relapsed/refractory CLL
• Progression free survival and safety results after 5 years of follow-up from the ELEVATE-TN phase III study of Acalabrutinib ± Obinutuzumab vs 
  Obinutuzumab + Chlorambucil as first-line therapy in CLL
• Assessments of whether racial and/or ethnic identity, and socioeconomic status are prognostic factors of survival in CLL

Presenter

John M. Burke, MD
Rocky Mountain Cancer Centers
Aurora, Colorado

Moderator 

Amy Esposito, FNP-C
Nurse Practitioner
Rocky Mountain Cancer Center
Aurora, Colorado